RA’ANANA, Israel - Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN), a micro-cap medical device company with a market capitalization of approximately $16 million, has announced the generation of its first revenues following the delivery and installation of its INSPIRA ART100 life support systems at a leading U.S. academic medical center. The company, which specializes in advanced life-support and diagnostic technologies, disclosed that the revenue amounts to the low hundreds of thousands of dollars. According to InvestingPro data, the stock has experienced significant volatility, with shares down about 68% over the past year.
The INSPIRA ART100 systems, recently installed, are FDA-cleared for use in cardiopulmonary bypass procedures, a critical function during cardiac surgeries. These systems operate by circulating and oxygenating blood outside the patient’s body. Inspira is now planning to install additional ART100 systems at a second prominent academic medical center.
Dagi Ben-Noon, Chief Executive Officer of Inspira, expressed that this revenue milestone is transformative for the company as it begins to establish its presence in the U.S. medical market. He emphasized the importance of this achievement in validating the company’s technology and its capability to collaborate with top-tier medical institutions. InvestingPro analysis indicates the company faces financial challenges, with a weak overall Financial Health Score of 1.74 and significant cash burn. Subscribers can access 6 additional ProTips and detailed financial metrics to better understand the company’s position.
Inspira’s expansion strategy also includes further collaborations with medical experts and institutions to validate its innovative approach to extracorporeal life support. The company’s broader product pipeline includes the INSPIRA ART500 system, which is under development and aims to provide a safer alternative to mechanical ventilation by allowing patients to remain awake during treatment.
The ART500 system is designed to target the $19 billion mechanical ventilation market by offering direct blood oxygenation for patients with respiratory failure without the need for mechanical ventilation. Additionally, Inspira is developing the HYLA blood sensor technology for real-time, continuous blood monitoring without blood draws. However, these products, including the ART500 system, HYLA blood sensor, and single-use patient kits, have not yet received regulatory approval.
Inspira Technologies’ press release statement indicates that the company is making strides in its deployment strategy and continues to pursue growth within the U.S. healthcare market. The information provided is based on the company’s recent press release. InvestingPro data suggests the stock is currently overvalued relative to its Fair Value, with a current ratio of 2.02 indicating adequate short-term liquidity despite negative earnings of -$0.60 per share over the last twelve months. Investors seeking deeper insights into medical technology stocks can explore comprehensive financial metrics and valuations through an InvestingPro subscription.
In other recent news, Inspira Technologies has shared updates on its strategic progress and upcoming milestones, highlighting its focus on the development of the INSPIRA ART500 system for respiratory care. The company plans to submit this system for FDA approval within the next 18 months, aiming to address the mechanical ventilation market, which is valued at $19 billion annually. Additionally, Inspira is facing a Nasdaq delisting notice due to non-compliance with the minimum bid price rule, requiring the company to maintain a closing bid price of at least $1.00 for ten consecutive business days by September 8, 2025. Inspira is exploring options, including a possible reverse share split, to meet this requirement.
In collaboration with Ennocure MedTech Ltd., Inspira has announced promising initial results from testing a bio-electronic patch that reduces bacterial presence by 95% within four hours, offering a non-chemical approach to infection prevention. This development could benefit patients suffering from bloodstream infections related to intravenous lines. The patch’s effectiveness was validated against standardized antimicrobial performance protocols, although it has not yet received regulatory approval. Inspira’s ongoing innovations in respiratory support and diagnostics, including the INSPIRA ART system and HYLA blood sensor, remain in various stages of development and regulatory approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.